Aarhus-based PipeBio has been acquired by Benchling, marking a new phase in the integration of bioinformatics and cloud-based software for biologics research. PipeBio, known for its cloud-native platform that facilitates the screening and analysis of large-scale biological sequences, will now operate under the Benchling umbrella, bringing its expertise to a broader technological ecosystem. With this acquisition, PipeBio aims to leverage Benchling’s extensive resources and integration capabilities to refine its offerings. The collaboration is expected to improve the efficiency of the discovery process by combining PipeBio’s advanced sequence analysis tools with Benchling’s established software ecosystem.
Founded in 2020, PipeBio developed a cloud-native bioinformatics tool that allows scientists to screen and analyze millions of sequences, helping them identify key candidates for biologics development. Their platform excels at high-throughput antibody screening, data visualization, and hit selection, making it a valuable asset for researchers aiming to develop new therapeutics.
Over the years, PipeBio has built a reputation for bridging the gap between large-scale experimental data and computational-driven drug design, a trend that is reshaping the landscape of biologics research. The company has already established an integration with Benchling, receiving positive feedback from shared customers, which demonstrated the potential for a more seamless and comprehensive solution.
Biologics, particularly antibodies, are becoming increasingly important in modern drug pipelines, driving the need for adaptable, innovative tools that can handle the complexities of these new therapeutic modalities. By acquiring PipeBio, Benchling enhances its ability to support scientists working on cutting-edge antibody workflows, from the initial screening of vast sequence libraries to the engineering and development of clinical candidates.
Both companies share a vision of accelerating biologics research through intuitive, scalable software that allows R&D teams to work more efficiently. PipeBio will continue to operate as usual, now bolstered by Benchling’s extensive resources and market reach. This partnership marks a significant step in the evolution of AI-driven drug discovery, setting the stage for future innovations in the biologics space.
Benchling has expressed enthusiasm about the acquisition, emphasizing their commitment to building the next generation of solutions for biologics R&D. As approaches to drug discovery shift toward computational design, the combination of Benchling and PipeBio promises to be a powerful driver of scientific progress, providing researchers with the tools they need to bring new therapeutics to the clinic faster and more effectively.
Click here to read more IPO/M&A news.
Read the orginal article: https://arcticstartup.com/pipebio-acquired-by-benchling/
